This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Galena Biopharma Inc (GALE)

NASDAQ: Health Care

Company Cash Flow
Dec 2014 Dec 2013 Dec 2012 Dec 2011
Cash Flow From Operating Activities
Net Income (Loss) -36.61M -76.68M -34.97M -11.48M
Operating Gains/Losses 0.00 -3.91M 0.00 907.00K
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables 1.64M -3.68M 0.00 0.00
(Increase) Decrease in Inventories -269.00K -386.00K 0.00 0.00
(Increase) Decrease In Other Current Assets 0.00 0.00 0.00 0.00
(Decrease) Increase In Payables -389.00K 684.00K 641.00K 500.00K
(Decrease) Increase In Other Current Liabilities 4.25M 6.73M -139.00K 1.34M
(Increase) Decrease In Other Working Capital 0.00 0.00 0.00 717.00K
Other Non-Cash Items -11.14M 47.67M 14.90M -6.81M
Net Cash From Continuing Operations -42.87M -28.91M -20.96M -14.67M
Net Cash From Discontinued Operations 0.00 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities -42.87M -28.91M -20.96M -14.67M
Sale of Property, Plant & Equipment 0.00 0.00 0.00 0.00
Cash Used for Investing Activities
Sale of Short-Term Investments 0.00 3.91M 0.00 0.00
Purchases of Property, Plant & Equipment -5.53M -15.85M 0.00 -53.00K
Acquisitions 0.00 0.00 0.00 168.00K
Purchases of Short-Term Investments 0.00 0.00 0.00 0.00
Other Cash from Investing Activities 0.00 -99.00K -87.00K -101.00K
Cash Provided by Financing Activities
Net Cash From Investing Activities -5.53M -12.04M -87.00K 14.00K
Issuance of Debt 0.00 9.87M 500.00K 500.00K
Cash Used for Financing Activities
Issuance of Capital Stock 26.03M 8.54M 42.20M 18.78M
Repayment of Long-Term Debt -1.77M -25.00K -10.00K -84.00K
Repurchase of Capital Stock 0.00 0.00 -266.00K 0.00
Payment of Cash Dividends 0.00 0.00 0.00 0.00
Other Financing Charges, Net 0.00 37.54M 0.00 0.00
Net Cash From Financing Activities 24.26M 55.92M 42.42M 19.20M
Effect of Exchange Rate Changes 0.00 0.00 0.00 0.00
Net Change in Cash & Cash Equivalents -24.14M 14.98M 21.37M 4.54M

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

GALE Galena Biopharma Inc

Chart of GALE

Analysts Ratings for GALE

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 5 3 3 3
Moderate Buy 1 1 1 0
Hold 0 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1

GALE Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs